Researchers are working on developing antigens to support the humanization of antibodies for the Crimean-Congo hemorrhagic fever virus. This effort involves the structural characterization of protective non-neutralizing antibodies that target the virus. The goal of this work appears to be related to developing a potential treatment or prevention method for the disease.